Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2/3 study of ALE 1 in HPP patients

Trial Profile

A 2/3 study of ALE 1 in HPP patients

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 14 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OC-1 (Primary)
  • Indications Hypophosphatasia
  • Focus Adverse reactions

Most Recent Events

  • 14 Jan 2026 New trial record
  • 06 Jan 2026 According to an Alesta media release, together with insights from the ongoing healthy volunteer study and an ongoing HPP patient observational study, these data are expected to inform the ALE1 clinical development path and Phase 2b/3 design.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top